Supplementary Tables 1 through 8 and Supplementary Figures 1 through 3 from Association of Estrogen Metabolism with Breast Cancer Risk in Different Cohorts of Postmenopausal Women

Abstract

<p>Supplementary Table 1A: The Pearson correlation coefficient of untransformed metabolite levels was estimated between each pair of metabolites within each of the four studies. Supplementary Table 1B: The Pearson correlation coefficient of untransformed metabolite levels was estimated between each of the metabolic pathway groups within each of the four studies. Supplementary Table 2A.: We evaluated the odds ratio (OR) of breast cancer in women with estrogen levels in the 2nd, 3rd, 4th, and 5th quintiles of each study, as compared to women in the lowest quintile, using analyses that did not adjust for any other estrogen variable. Supplementary Table 2B.: We evaluated the OR of breast cancer in women with analyte/path:Total ratios in the 2nd, 3rd, 4th, and 5th quintiles of each study, as compared to women in the lowest quintile, using analyses that adjusted for total estrogen level. Supplementary Table 3: Inter-decile odds ratios (ORs) and 95% confidence intervals from each study contributing to the meta-analysis of all studies for analyte:total ratios from models adjusted for total estrogen level. Supplementary Table 4: Inter-decile odds ratios (ORs) and 95% confidence intervals from each study contributing to the meta-analysis of all studies for analyte:total ratios from models adjusted for total estrogen level. Supplementary Table 5: Inter-decile odds ratios (ORs) and 95% confidence intervals (CIs) from random effects meta-analysis of all studies for estrogen levels, unadjusted for total estrogen levels, and inter-decile ORs and 95% CIs from random effects meta-analysis for analyte:total ratios from models adjusted for total estrogen level. Supplementary Table 6: Inter-decile odds ratios (ORs) for Path2:Path16 ratio within subgroups of individuals using models adjusted for total estrogen level. Supplementary Table 7: We classified women into 9 groups, defined by tertiles of total estrogen level and tertiles of Path-2:Path-16 ratio. Supplementary Table 8: We measured the association between the Path-2:Path-16 ratio (dependent variable) and each of the covariates listed in the first column (independent variable). Supplementary Figure 1: The Path-2:Path-16 ratio is plotted as a function of the log of the total estrogen level within each study. Supplementary Figure 2: Odds ratios and 95% confidence intervals comparing the risk of breast cancer in individuals with a higher analyte or pathway concentration (90th percentile) to individuals with a lower concentration (10th percentile). Supplementary Figure 3: Odds ratios and 95% confidence intervals comparing the risk of breast cancer in individuals with a higher analyte:total or pathway:total ratio (90th percentile) to individuals with a lower ratio (10th percentile).</p>